TY - JOUR T1 - Low awareness of past SARS-CoV-2 infection in healthy adults JF - medRxiv DO - 10.1101/2020.08.10.20171561 SP - 2020.08.10.20171561 AU - Katja van den Hurk AU - Eva-Maria Merz AU - Femmeke J. Prinsze AU - Marloes L.C. Spekman AU - Franke A. Quee AU - Steven Ramondt AU - Ed Slot AU - Hans Vrielink AU - Elisabeth M.J. Huis in ’t Veld AU - Hans L. Zaaijer AU - Boris M. Hogema Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/12/2020.08.10.20171561.abstract N2 - Background The coronavirus disease 2019 (COVID-19) pandemic challenges governments worldwide to balance appropriate virus control measures and their societal and economic consequences. These control measures include the identification, isolation and testing of potentially infected individuals. As this relies on an individual’s awareness of infection, we investigated the extent to which healthy adults suspected having had COVID-19, and how COVID-19 suspicion and symptoms relate to antibodies indicative of a past infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Methods and findings For this cross-sectional study, individuals donating plasma anywhere in the Netherlands between May 11th and 18th were screened for total SARS-CoV-2 antibodies using ELISA and invited to participate in an online questionnaire about COVID-19-related symptoms and awareness. Antibody and questionnaire data were complete for 3,676 individuals, including 239 (6.5%) that tested positive for SARS-CoV-2 antibodies. Here, we show that a 38% of the individuals that tested positive for SARS-CoV-2 antibodies reported having had no or only very mild symptoms at any time during the peak of the epidemic. The loss of taste and/or smell in particular was significantly associated with seropositivity, independent of age and sex. Forty-eight percent of antibody-positive persons did not suspect having had COVID-19, in spite of most of them reporting symptoms.Conclusions Awareness of infection was low among individuals that tested positive for SARS-CoV-2 antibodies, even at the peak of the epidemic. Improved awareness and recognition of COVID-19 symptoms and tracing of asymptomatic contacts is crucial to halting SARS-CoV-2 transmission.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN.A.Funding StatementThe study has been funded by Sanquin Blood Supply Foundation and the Dutch Ministry of Health, Welfare and Sport. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participating individuals gave informed consent before participating in the online questionnaire and the study protocol and procedures were approved by Sanquin's Ethics Advisory Council and its Privacy Officer.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analyzed in the context of this study are available from the corresponding author upon reasonable request. ER -